Elsevier

Clinical Therapeutics

Volume 28, Issue 7, July 2006, Pages 1044-1053
Clinical Therapeutics

Patient characteristics and patterns of drug use for sleep complaints in the united states: Analysis of national ambulatory medical survey data, 1997–2002

https://doi.org/10.1016/j.clinthera.2006.07.008Get rights and content

Abstract

Objective:

The aims of this work were to characterize ambulatory patients in the United States presenting with primary or secondary insomnia complaints and resultant diagnoses, and to describe the characteristics of patients treated with medications commonly used for sleep complaints.

Methods:

Data from the National Ambulatory Medical Care Survey for the years 1997 through 2002 were analyzed. Data were stratified by patient characteristics, physician specialty, resulting diagnosis, and medications prescribed or provided. The unit of analysis was the individual patient visit; statistical comparisons were made using the χ2 test for categorical variables and the Rao-Scott design-adjusted χ2 test for comparisons of patient age groups. P<0.05 was the criterion for statistical significance. Cells containing < 30 observations were not included in the statistical analysis.

Results:

The data included 147,945 patient visit records; rates of physician response to the survey ranged from 62.9% in 1999 to 70.4% in 2002. Based on this sample, it was projected that 30 million office visits involved insomnia complaints over the 6-year period from 1997 to 2002 throughout the United States. With a total of 4.9 billion physician visits projected for that time period, 0.6% of visits were insomnia related. Women were 1.5 times more likely to have insomnia-related visits (P<0.001). Overall, the greatest proportion of insomnia patients of both sexes was between the ages of 18 and 64 years (P<0.001). Sleep difficulties were most frequently attributed to organic disorders, depression and/or anxiety, and primary insomnia (55.8%, 27.3%, and 9.8%, respectively; P<0.001). The most frequently prescribed or recommended medications were zaleplon/zolpidem and trazodone (28.5% and 32.0%, respectively; P<0.001). Zaleplon and zolpidem were most frequently used for patients with organic diagnoses and those aged ≤65 years (33.2% and 29.8%; P<0.001).

Conclusions:

Demographics of patients with insomnia and their diagnoses from 1999 to 2002 remained stable, but the use of medications changed predictably as newer agents became available.

References (32)

  • OhayonMM

    Prevalence and correlates of nonrestorative sleep complaints

    Arch Intern Med

    (2005)
  • LegerD et al.

    Health-related quality of life in patients with insomnia treated with zopiclone

    PharmacoEconomics

    (1996)
  • StollerMK

    Economic effects of insomnia

    Clin Ther.

    (1994)
  • OhayonMM et al.

    Place of chronic insomnia in the course of depressive and anxiety disorders

    J Psychiatr Res.

    (1993)
  • Martinez-GonzalezD et al.

    Comorbidity of insomnia with medical and psychiatric disorders

    Prim Psychiatr

    (2002)
  • KalesA et al.

    Office management of sleep disorder patients

    Psychiatr Ann.

    (1987)
  • Cited by (62)

    • Healthy sleep: basic sleep tips

      2023, Encyclopedia of Sleep and Circadian Rhythms: Volume 1-6, Second Edition
    • Zolpidem increases GABA in depressed volunteers maintained on SSRIs

      2014, Psychiatry Research - Neuroimaging
      Citation Excerpt :

      The study design was based on previous work in healthy volunteers showing a reduction in GABA following acute administration of zolpidem (Licata et al., 2009), and predicted that in addition to reduced GABA, self-reported subjective drug assessments administered periodically throughout the experimental session would reveal effects indicative of a negative mood state. Together these measures were aimed at understanding more about the neurobiological mechanisms that contribute to the behavioral effects of this popular hypnotic (Morlock et al., 2006), particularly in depressed individuals. Fourteen volunteers (4 male and 10 female) between the ages of 21–40 (mean±standard deviation [SD] 29.6±5.1 years) completed this study.

    • The hypnotic zolpidem increases the synchrony of BOLD signal fluctuations in widespread brain networks during a resting paradigm

      2013, NeuroImage
      Citation Excerpt :

      The present study employed BOLD fMRI to investigate the modulation of RSNs by zolpidem in healthy volunteers as a means for beginning to reveal the neurobiological correlates of sedative/hypnotic action. Zolpidem (Ambien®) is a positive allosteric modulator of γ-aminobutyric acidA (GABAA) receptors, and it is one of the most frequently prescribed sleep aids in the United States (Morlock et al., 2006). Zolpidem's interaction with GABAA receptors underlies its clinical effectiveness as a hypnotic (Lloyd and Zivkovic, 1988), but this mechanism of action alone does not provide sufficient explanation for zolpidem's superiority in the treatment of insomnia.

    View all citing articles on Scopus
    View full text